DexCom Beheer

Beheer criteriumcontroles 3/4

De CEO DexCom is Kevin Sayer, benoemd in Jun2011, heeft een ambtstermijn van 13.33 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 15.71M, bestaande uit 7% salaris en 93% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.045% van de aandelen van het bedrijf, ter waarde R$ 72.55M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.6 jaar en 8.8 jaar.

Belangrijke informatie

Kevin Sayer

Algemeen directeur

US$15.7m

Totale compensatie

Percentage CEO-salaris	7.0%
Dienstverband CEO	13.3yrs
Eigendom CEO	0.04%
Management gemiddelde ambtstermijn	3.6yrs
Gemiddelde ambtstermijn bestuur	8.8yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Kevin Sayer's beloning veranderd ten opzichte van DexCom's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	US$681m
Jun 30 2024	n/a	n/a	US$667m
Mar 31 2024	n/a	n/a	US$639m
Dec 31 2023	US$16m	US$1m	US$542m
Sep 30 2023	n/a	n/a	US$377m
Jun 30 2023	n/a	n/a	US$358m
Mar 31 2023	n/a	n/a	US$293m
Dec 31 2022	US$15m	US$953k	US$341m
Sep 30 2022	n/a	n/a	US$244m
Jun 30 2022	n/a	n/a	US$230m
Mar 31 2022	n/a	n/a	US$258m
Dec 31 2021	US$12m	US$900k	US$217m
Sep 30 2021	n/a	n/a	US$577m
Jun 30 2021	n/a	n/a	US$562m
Mar 31 2021	n/a	n/a	US$530m
Dec 31 2020	US$14m	US$800k	US$550m
Sep 30 2020	n/a	n/a	US$231m
Jun 30 2020	n/a	n/a	US$205m
Mar 31 2020	n/a	n/a	US$148m
Dec 31 2019	US$10m	US$691k	US$101m
Sep 30 2019	n/a	n/a	-US$171m
Jun 30 2019	n/a	n/a	-US$170m
Mar 31 2019	n/a	n/a	-US$130m
Dec 31 2018	US$10m	US$601k	-US$127m
Sep 30 2018	n/a	n/a	US$43m
Jun 30 2018	n/a	n/a	-US$5m
Mar 31 2018	n/a	n/a	-US$33m
Dec 31 2017	US$8m	US$546k	-US$50m

Compensatie versus markt: De totale vergoeding ($USD 15.71M ) Kevin } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de BR markt ($USD 5.78M ).

Compensatie versus inkomsten: De vergoeding van Kevin is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Kevin Sayer (66 yo)

13.3yrs

Tenure

US$15,712,244

Compensatie

Mr. Kevin Ronald Sayer has been Executive Chairman of DexCom, Inc. since July 30, 2018. Mr. Sayer has been the Chief Executive Officer of DexCom, Inc. since January 5, 2015 and as its President since June...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Kevin Sayer	Executive Chairman	13.3yrs	US$15.71m	0.045% R$ 72.6m
Jereme Sylvain	Executive VP	4.6yrs	US$4.25m	0.0090% R$ 14.7m
Jacob Leach	Executive VP & COO	2.2yrs	US$4.94m	0.066% R$ 107.7m
Michael Brown	Executive VP & Chief Legal Officer	2.8yrs	US$4.34m	0.0014% R$ 2.2m
Teri Lawver	Executive VP & Chief Commercial Officer	1.8yrs	US$6.53m	0.0017% R$ 2.7m
Girish Naganathan	Executive VP & CTO	2yrs	US$4.05m	0.0014% R$ 2.2m
Sean Christensen	Director of Corporate Affairs & Head of Investor Relations	no data	geen gegevens	geen gegevens
Matthew Dolan	Executive Vice President of Strategy	3.6yrs	geen gegevens	0% R$ 0
Leverne Marsh	Executive Vice President of Marketing	less than a year	geen gegevens	geen gegevens
Sadie Stern	Executive VP & Chief Human Resources Officer	4.1yrs	geen gegevens	0.0059% R$ 9.6m
Donald Abbey	Executive Vice President of Global Business Services	7.8yrs	US$2.92m	0.043% R$ 70.3m
Barry Regan	Executive Vice President of Global Operations	3.9yrs	geen gegevens	0.0020% R$ 3.2m

3.6yrs

Gemiddelde duur

50yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van D1EX34 wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.6 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Kevin Sayer	Executive Chairman	16.9yrs	US$15.71m	0.045% R$ 72.6m
Mark Foletta	Lead Independent Director	9.9yrs	US$393.51k	0.014% R$ 23.5m
Steven Altman	Independent Director	10.9yrs	US$343.40k	0.014% R$ 23.3m
Eric Topol	Independent Director	15.3yrs	US$346.49k	0.097% R$ 157.4m
Nicholas Augustinos	Independent Director	14.9yrs	US$362.21k	0.0095% R$ 15.4m
Bridgette Heller	Independent Director	5.1yrs	US$346.49k	0.0056% R$ 9.0m
Kyle Malady	Independent Director	4yrs	US$343.40k	0.0040% R$ 6.5m
Karen Dahut	Independent Director	4.2yrs	US$345.90k	0.0039% R$ 6.3m
Richard Collins	Independent Director	7.6yrs	US$345.90k	0.010% R$ 16.4m
Rimma Driscoll	Independent Director	1.2yrs	US$404.72k	0% R$ 0

8.8yrs

Gemiddelde duur

63yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van D1EX34 wordt beschouwd als ervaren (gemiddelde ambtstermijn 8.8 jaar).

DexCom Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

DexCom, Inc., Annual General Meeting, May 22, 2024

DexCom, Inc., Annual General Meeting, May 22, 2024

DexCom, Inc. Announces Appointment of Rimma Driscoll to Its Board of Directors

DexCom, Inc. Promotes Jacob S. Leach to Chief Operating Officer

DexCom, Inc. Announces Resignation of Chad M. Patterson as Executive Vice President, Global Marketing, Effective July 15, 2022

DexCom Announces Retirement of Rick Doubleday as Executive Vice President and Chief Commercial Officer

Recent updates

DexCom, Inc. Reiterates Earnings Guidance for the Fiscal Year 2024

Kessler Topaz Meltzer & Check, LLP Files Class Action Lawsuit Against Dexcom, Inc

DexCom, Inc. to Showcase Transformational Impact of Dexcom CGM Technology at the EASD 2024 Conference Symposium

Stelo by Dexcom, the First Over-The-Counter Glucose Biosensor in the U.S., Is Now Available

Levi & Korsinsky, LLP Files Complaint to Recover Losses Suffered by Purchasers of DexCom, Inc

DexCom, Inc. Updates Earnings Guidance for the Year 2024

DexCom, Inc. to Report Q2, 2024 Results on Jul 25, 2024

Dexcom Showcases Extensive Clinical Data At ADA 2024 Demonstrating the Benefit of Dexcom CGM Use Among People with Type 2 Diabetes

Dexcom, Inc. Announces the Dexcom G7 Continuous Glucose Monitoring System Now Connects Directly to Apple Watch in the United States

Dexcom Wins Access to Dexcom One for 100,000 People Living with Type 2 Diabetes

DexCom, Inc. Provides Earnings Guidance for the Year 2024

DexCom, Inc., Annual General Meeting, May 22, 2024

DexCom, Inc., Annual General Meeting, May 22, 2024

DexCom, Inc. to Report Q1, 2024 Results on Apr 25, 2024

DexCom, Inc. Announces the FDA Clears Stelo by Dexcom – the First Glucose Biosensor

DexCom, Inc. Reiterates Revenue Guidance for the Fiscal Year 2024

DexCom, Inc. Launches Dexcom One+ Bringing Powerful, New Diabetes Management Technology to More People

Dexcom, Inc. Announces the Dexcom G7 Continuous Glucose Monitoring System Now Connects with the t:Slim X2™ Insulin Pump by Tandem Diabetes Care in Countries Across Europe and in South Africa

DexCom, Inc. to Report Q4, 2023 Results on Feb 08, 2024

Dexcom, Inc. Provides Revenue Guidance for the Full Year of 2024

Dexcom, Inc. Announces the Dexcom G7 Continuous Glucose Monitoring System Now Connects with the Tandem t:slim X2 Insulin Pump

DexCom, Inc. (NasdaqGS:DXCM) announces an Equity Buyback for $500 million worth of its shares.

Dexcom Solidifies Global Leadership in Continuous Glucose Monitoring with New Clinical Data Presented at EASD

DexCom, Inc. to Report Q3, 2023 Results on Oct 26, 2023

DexCom, Inc Announces the Availability of Its Dexcom One Real-Time CGM Sensor Via Reimbursement, in France

DexCom, Inc. Announces Appointment of Rimma Driscoll to Its Board of Directors

DexCom, Inc. Increases Earnings Guidance for the Fiscal Year 2023

DexCom, Inc. to Report Q2, 2023 Results on Jul 27, 2023

Dexcom, Inc. Receives Health Canada Approval: Next-Generation Continuous Glucose Monitoring System with Unmatched Accuracy Coming to Canadians

DexCom, Inc. Updates Earnings Guidance for the Year 2025

DexCom, Inc. Reiterates Revenue Guidance for the Fiscal Year 2023

Dexcom, Inc.'s G6 Real-Time CGM System Now Available to All Clients With Type 1 Diabetes Covered Under the Non-Insured Health Benefits Program

DexCom, Inc. to Report Q4, 2022 Results on Feb 09, 2023

Dexcom, Inc. Receives FDA Clearance of Next-Generation Dexcom G7 Continuous Glucose Monitoring System

DexCom, Inc. Provides Earnings Guidance for the Year 2022

DexCom, Inc. Announces the Launch of Dexcom U

DexCom, Inc. Announces Launch of Dexcom G7 in the United Kingdom, Ireland, Germany, Austria and Hong Kong – Initiating Global Rollout of World’s Most Powerful Continuous Glucose Monitoring System

DexCom, Inc. to Report Q3, 2022 Results on Oct 27, 2022

DexCom, Inc. Promotes Jacob S. Leach to Chief Operating Officer

DexCom, Inc. Announces One Real-Time Continuous Glucose Monitoring (rt-CGM) System Available on Prescription in the UK

DexCom, Inc. (NasdaqGS:DXCM) announces an Equity Buyback for $700 million worth of its shares.

DexCom, Inc. Revises Earnings Guidance for the Full Year 2022

DexCom, Inc. Announces Resignation of Chad M. Patterson as Executive Vice President, Global Marketing, Effective July 15, 2022

DexCom, Inc. to Report Q2, 2022 Results on Jul 28, 2022

Dexcom Says Not in Active Merger Talks

Dexcom Reportedly in Talks to Acquire Insulet

DexCom, Inc. Showcases Expanded CGM Portfolio at International ATTD Conference

Dexcom Announces Dexcom ONE, the Newest Real-Time Continuous Glucose Monitoring System, to Its Range of Scan-Free and Fingerprick†-Free Devices

DexCom, Inc. to Report Q1, 2022 Results on Apr 28, 2022

DexCom, Inc. Reiterates Earnings Guidance for the Fiscal Year 2022

Dexcom, Inc. Reports Preliminary Unaudited Revenue Guidance for the Fourth Quarter and Fiscal Year Ended December 31, 2021; Revenue Guidance for the Fiscal Year 2022

Dexcom G6 Continuous Glucose Monitoring System Now Covered in Manitoba for Young People with Type 1 Diabetes

Dexcom, Inc. Announces Non-insured Health Benefits Program Covers Dexcom G6 Continuous Glucose Monitoring System for Children and Adolescents on Intensive Insulin Therapy

FDA Clears DexCom, Inc.'s Real-Time APIs for Third-Party Apps and Devices

DexCom, Inc.(NasdaqGS:DXCM) dropped from Russell Top 200 Index

DexCom, Inc. Announces Results of Two New Studies Illustrate Continued Momentum for Dexcom CGM, Including JAMA-Published Data on Additional Populations Who Can Benefit from the Technology

DexCom, Inc. (NasdaqGS:DXCM) acquired assets in the Netherlands, Belgium and Luxembourg from a Dexcom distributor.

DexCom, Inc. Increasing Revenue Guidance for Fiscal Year 2021

DexCom, Inc. Announces Launch of Dexcom Ventures

Everside Health's Legacy Healthstat Partners with Dexcom to Provide Continuous Glucose Monitoring for Type 2 Diabetes

DexCom, Inc. to Report Q4, 2020 Results on Feb 11, 2021

DexCom, Inc. Revises Revenue Guidance for Fiscal Year 2020

DexCom Announces Retirement of Rick Doubleday as Executive Vice President and Chief Commercial Officer

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur